
Texas-based KALA BIO, Inc. is a clinical-stage biopharmaceutical company, innovating drug delivery for mucosal tissues globally.
KALA BIO, Inc., founded in Arlington, Texas, is a clinical-stage biopharmaceutical company dedicated to addressing rare and serious eye diseases. The company's core mission is to develop innovative therapies that leverage advanced science to penetrate mucosal tissues such as the eyes, lungs, gastrointestinal tracts, and female reproductive systems. KALA BIO's primary focus is on the research and development of mesenchymal stem cell secretome (MSC-S) therapies, aiming to provide regenerative healing effects for ocular surface and retinal diseases, ultimately preserving vision.
Notable figures affiliated with KALA BIO include leading scientists and researchers in the field of biopharmaceuticals. The company has attracted significant investment from prominent venture capital firms specializing in healthcare and biotechnology. Key achievements include the successful development of their proprietary MSC-S platform and the progression of several therapies into clinical trials. KALA BIO's impact is marked by its potential to revolutionize treatment for rare eye diseases, offering hope and improved quality of life for patients worldwide.

KaloBios Pharmaceuticals
kalobios.com

Qlaris Bio
qlaris.bio

Cell Care Therapeutics
cell-care.com

Beilai Bio
baylxinc.com

EyeCyte
eyecyte.com

Ocular Therapeutix
ocutx.com

Surface Pharmaceuticals
surfacepharma.com

PMGC Holdings

Kriya Therapeutics

KaloCyte
kalocyte.com

RainBio
rainbio.us

Kallyope
kallyope.com

Tela Bio
telabio.com

Kezar Life Sciences

LaCell
Companies similar to KALA BIO include KaloBios Pharmaceuticals, Qlaris Bio, Cell Care Therapeutics and Beilai Bio.
KALA BIO was founded in 2009.
KALA BIO's headquarters is located in Arlington, MA, US.
KALA BIO has 34 employees as of Feb 6, 2024.